Trial Profile
A clinical trial of NOX-E36 in solid tumors both as a monotherapy and in combination
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 02 Nov 2020
Price :
$35
*
At a glance
- Drugs Emapticap pegol (Primary)
- Indications Pancreatic cancer; Solid tumours
- Focus Therapeutic Use
- 29 Oct 2020 According to a NOXXON Pharma AG media release, this study is expected to be initiated in 2021.
- 21 Jun 2018 New trial record